✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Talazoparib tosylateis the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Talazoparib tosylate has ninety-one patent family members in thirty countries.
Two suppliers are listed for this compound.
Recent Clinical Trials for talazoparib tosylate
Identify potential brand extensions & 505(b)(2) entrants
|Stanford University||Phase 2|
|Roswell Park Cancer Institute||Phase 1|
Pharmacology for talazoparib tosylate
|Drug Class||Poly(ADP-Ribose) Polymerase Inhibitor |
|Mechanism of Action|| Poly(ADP-Ribose) Polymerase Inhibitors |
|Country||Patent Number||Title||Estimated Expiration|
|South Korea||20190120458||결정질의 (8S,9R)-5-플루오로-8--9-(1-메틸-1H-1,2,4-트리아졸-5-일)-8,9-디하이드로-2H-피리도[4,3,2-DE]프탈라진-3(7H)-온 토실레이트 염 (8S9R-5--8-4--9-1--1H-124--5--89--2H-[432-DE]-37H- CRYSTALLINE 8S9R-5-FLUORO-8-4-FLUOROPHENYL-9-1-METHYL-1H-124-TRIAZOL-5-YL-89-DIHYDRO-2H-PYRIDO[432-DE]PHTHALAZIN-37H-ONE TOSYLATE SALT)||See Plans and Pricing|
|Cyprus||1115022||See Plans and Pricing|
|Russian Federation||2514937||ДИГИДРОПИРИДОФТАЛАЗИНОНОВЫЕ ИНГИБИТОРЫ ПОЛИ(АДФ-РИБОЗА)ПОЛИМЕРАЗЫ (DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE)||See Plans and Pricing|
|Taiwan||I448464||See Plans and Pricing|
|Brazil||PI0917119||composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação.||See Plans and Pricing|
|Portugal||2630146||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|2767537||2019042||Norway||See Plans and Pricing||PRODUCT NAME: TALAZOPARIB, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTERBART SALT; REG. NO/DATE: EU/1/19/1377 20190715|
|2767537||122019000108||Germany||See Plans and Pricing||PRODUCT NAME: TALAZOPARIB ODER PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1377 20190620|
|2767537||301021||Netherlands||See Plans and Pricing||PRODUCT NAME: TALAZOPARIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1377 20190624|
|2767537||CR 2019 00055||Denmark||See Plans and Pricing||PRODUCT NAME: TALAZOPARIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT; REG. NO/DATE: EU/1/19/1377 20190624|
|2767537||LUC00140||Luxembourg||See Plans and Pricing||PRODUCT NAME: TALAZOPARIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/19/1377 20190624|
|2767537||408 19-2019||Slovakia||See Plans and Pricing||PRODUCT NAME: TALAZOPARIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/19/1377 20190624|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.